» Articles » PMID: 26672083

CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2015 Dec 17
PMID 26672083
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

In the January 15, 2012, issue of Clinical Cancer Research, Kirkwood and colleagues published a study comparing the MEK inhibitor selumetinib with temozolomide in unselected metastatic melanoma. Although selumetinib did not improve survival or response, most responders had BRAF-activating mutations, and selumetinib has since demonstrated efficacy in BRAF-mutant melanoma. This study laid the groundwork for the evaluation of BRAF/MEK inhibitors in BRAF-mutant melanoma.

Citing Articles

Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs.

Wachter S, Wunderlich A, Greene B, Roth S, Elxnat M, Fellinger S Int J Mol Sci. 2018; 19(7).

PMID: 30018229 PMC: 6073679. DOI: 10.3390/ijms19072077.

References
1.
Curtin J, Fridlyand J, Kageshita T, Patel H, Busam K, Kutzner H . Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353(20):2135-47. DOI: 10.1056/NEJMoa050092. View

2.
Leach D, Krummel M, Allison J . Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271(5256):1734-6. DOI: 10.1126/science.271.5256.1734. View

3.
Haass N, Sproesser K, Nguyen T, Contractor R, Medina C, Nathanson K . The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res. 2008; 14(1):230-9. DOI: 10.1158/1078-0432.CCR-07-1440. View

4.
Hainsworth J, Cebotaru C, Kanarev V, Ciuleanu T, Damyanov D, Stella P . A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010; 5(10):1630-6. DOI: 10.1097/JTO.0b013e3181e8b3a3. View

5.
Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P . A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs. 2010; 29(5):1021-8. DOI: 10.1007/s10637-010-9392-8. View